PCSK9 Cholesterol Drugs And FDA’s Missing Mandatory Study Authority
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee seems conflicted about when LDL-lowering can be fully valid surrogate endpoint, but issue would probably be a lot simpler for FDA – and sponsors – if FDA had authority to mandate trials for efficacy.
You may also be interested in...
IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?
Sponsors of injectable PCSK9 biologics address questions about the implications of the IMPROVE-IT study, in which the soon-to-be-generic oral Zetia helped bring down LDL cholesterol to a very low level.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.